We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Triosyn of Williston, Vt., has received certification
from The National Institute of Occupational Safety and Health for the company's
new T-300 respirator.
Smiths Medical has received FDA 510(k) premarket notification clearance and
CE mark for its new PORT-A-CATH II RDD Arterial Access System for the treatment
of liver cancer.
Inovio Biomedical announced that Merck has exercised an option for a nonexclusive
license for an additional antigen to be used with Inovio's MedPulser DNA Delivery
System, which is being developed for use with certain of Merck's DNA vaccine
research programs.
Spectranetics, a developer, manufacturer and marketer of single-use medical
devices used in minimally invasive cardiovascular procedures, has recently received
510(k) clearance from the FDA to market its enhanced lead locking device (LLD
E).
Derma Sciences, a manufacturer and full line supplier of wound and skin care
products, announced it has entered into an agreement with Source Medical under
which Source will become Derma's exclusive distributor of the company's products
to the Canadian market.
Abiomed, a manufacturer of products for circulatory care and support, announced
the completion of its acquisition of Impella CardioSystems AG, a privately held
company located in Aachen, Germany.
Sparton announced that it has signed a binding letter of intent for Sparton
to acquire the HDJ Company and its wholly owned subsidiary, Specialized Medical
Devices.
Power3 Medical Products has submitted a pre-IDE (investigational device exemption)
application with the Division of Hematology of the FDA for the company's NuroPro
Blood Tests for the early detection and differentiation of neuromuscular and
neurodegenerative diseases, such as ALS and Parkinson's disease.
CombiMatrix has formed a wholly owned subsidiary, CombiMatrix Molecular Diagnostics,
to develop DNA microarrays for molecular diagnostics, Acacia Research announced.
Olympus Biomaterial, Sumitomo Osaka Cement and Sumitomo Pharmaceuticals jointly
announced that they have reached a basic agreement on a forthcoming transfer
of bone replacement material business currently co-conducted by Sumitomo Osaka
Cement and Sumitomo Pharmaceuticals.